A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Clinical trial NCT04417517 · TERMINATED

Trial details

NCT number: NCT04417517
Sponsor: ALX Oncology Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Higher Risk Myelodysplastic Syndromes

Start date: 2020-10-02
Primary completion: 2025-01-17
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.